Mycophenolate Mofetil

MYCOPHENOLATE MOFETIL- mycophenolate mofetil injection, powder, lyophilized, for solution
Mylan Institutional LLC

WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS

Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1), Use in Special Populations (8.1, 8.3)].
Increased risk of development of lymphoma and other malignancies, particularly of the skin [see Warnings and Precautions (5.2)].
Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes [see Warnings and Precautions (5.3)].

1 INDICATIONS AND USAGE

Mycophenolate mofetil (MMF) for injection is indicated for the prophylaxis of organ rejection, in adult recipients of allogeneic kidney [see Clinical Studies (14.1)], heart [see Clinical Studies (14.2)] or liver transplants [see Clinical Studies (14.3)] , in combination with other immunosuppressants.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

Mycophenolate mofetil for injection should not be used without the supervision of a physician with experience in immunosuppressive therapy.

Mycophenolate Mofetil for Injection

Mycophenolate mofetil for injection is recommended for patients unable to take oral mycophenolate mofetil. Mycophenolate mofetil for injection should be administered within 24 hours following transplant. Mycophenolate mofetil for injection can be administered for up to 14 days; however, patients should be switched to oral mycophenolate mofetil as soon as they can tolerate oral medication.

Mycophenolate mofetil for injection must be reconstituted before use [see Dosage and Administration (2.6)]. Mycophenolate mofetil for injection is incompatible with other intravenous infusion solutions and should not be mixed or administered concurrently via the same infusion catheter with other intravenous drugs or infusion admixtures.

Mycophenolate mofetil for injection must not be administered as a bolus. Following reconstitution, mycophenolate mofetil for injection must be administered by slow intravenous infusion over a period of no less than 2 hours by either peripheral or central vein, as rapid infusion increases the risk of local adverse reactions such as phlebitis and thrombosis [see Adverse Reactions (6.1)].

2.2 Dosage Recommendations for Kidney Transplant Patients

Adults

The recommended dosage for adult kidney transplant patients is 1 g orally or intravenously infused over no less than 2 hours, twice daily (total daily dose of 2 g).

Pediatrics (3 months and older)

Pediatric dosing is based on body surface area (BSA). The recommended dosage of mycophenolate oral suspension for pediatric kidney transplant patients 3 months and older is 600 mg/m2 , administered twice daily (maximum total daily dose of 2 g or 10 mL of the oral suspension). Pediatric patients with BSA ≥ 1.25 m2 may be dosed with capsules or tablets as follows:

Table 1 Pediatric Kidney Transplant: Dosage Using Capsules or Tablets

Body Surface Area

Dosage

1.25 m2 to <1.5 m2

Mycophenolate capsule 750 mg twice daily (1.5 g total daily dose)

≥ 1.5 m2

Mycophenolate capsules or tablets 1 g twice daily (2 g total daily dose)

2.3 Dosage Recommendations for Heart Transplant Patients

Adults

The recommended dosage of mycophenolate mofetil for injection for adult heart transplant patients is 1.5 g orally or intravenously infused over no less than 2 hours administered twice daily (total daily dose of 3 g).

Pediatrics (3 months and older)

The recommended starting dosage of mycophenolate oral suspension for pediatric heart transplant patients 3 months and older is 600 mg/m2 , administered twice daily. If well tolerated, the dose can be increased to a maintenance dosage of 900 mg/m2 twice daily (maximum total daily dose of 3 g or 15 mL of the oral suspension). The dose may be individualized based on clinical assessment.

Pediatric patients with BSA ≥1.25 m2 may be started on therapy with capsules or tablets as follows:

Table 2 Pediatric Heart Transplant: Pediatric Starting Dosage Using Capsules or Tablets

Body Surface Area

Starting Dosage*

1.25 m2 to <1.5 m2

Mycophenolate capsule 750 mg twice daily (1.5 g total daily dose)

≥ 1.5 m2

Mycophenolate capsules or tablets 1 g twice daily (2 g total daily dose)

*Maximum maintenance dose: 3 g total daily.

2.4 Dosage Recommendations for Liver Transplant Patients

Adults

The recommended dosage of mycophenolate mofetil for injection for adult liver transplant patients is 1.5 g administered orally twice daily (total daily dose of 3 g) or 1 g infused intravenously over no less than 2 hours, twice daily (total daily dose of 2 g).

Pediatrics (3 months and older)

The recommended starting dosage of mycophenolate oral suspension for pediatric liver transplant patients 3 months of age and older is 600 mg/m2 , administered twice daily. If well tolerated, the dose can be increased to a maintenance dosage of 900 mg/m2 twice daily (maximum total daily dose of 3 g or 15 mL of the oral suspension). The dose may be individualized based on clinical assessment.

Pediatric patients with BSA ≥1.25 m2 may be started on therapy with capsules or tablets as follows:

Table 3 Pediatric Liver Transplant: Pediatric Starting Dosage Using Capsules or Tablets

Body Surface Area

Starting Dosage*

1.25 m2 to <1.5 m2

Mycophenolate capsule 750 mg twice daily (1.5 g total daily dose)

≥ 1.5 m2

Mycophenolate capsules or tablets 1 g twice daily (2 g total daily dose)

*Maximum maintenance dose: 3 g total daily.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.